St. Louis-based Defender Pharmaceuticals, with $70M in funding, eyes approval for lead drug candidate

A Town & County-based life sciences firm that has raised $70 million from investors hopes to soon be able to commercialize a drug candidate it has developed to prevent vomiting and nausea from motion sickness.

With closure of Vechos restaurant, changes are in the works at Granite Bay’s Quarry Ponds Town Center

Prominent Wichita credit union, restaurant brand ink NIL deals with KU, K-State stars

Here’s how much you need to make to afford a home in Louisville’s most expensive suburb

RISE Baymeadows on track to open units next summer

CBF Morning Run: What you need to know today and weighing the pain of driving to the torture of flying

Iconic Harley-Davidson dealership property in Florida sold to power further expansion

Microsoft buys Sterling lot where data center could go

Developers vs. City Hall: Deannexation clashes intensify

St. Louis-based Defender Pharmaceuticals, with $70M in funding, eyes approval for lead drug candidate

Previous Why UM's Sylvester Cancer Center is embracing diversity internship program

Next GNC unveils supplemental health care service for customers

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Hilton-branded hotel planned in Pompano Beach (Photos)

Destination Residences Hawaii tapped to manage new Hawaii development

Community First Credit Union member growth rate doubled in Q2

Trident Capital Group proposes $24 million industrial project in far east Columbus

Q&A: What Clear Blue Co.’s Nick Ogden learned financing his first affordable housing development

Saratoga speakeasy’s founders talk inspiration for new spot

MENU

FirstStar Group

More Stories

Meet Ameen Amin, a 40 Under 40 honoree